Beam Therapeutics (BEAM) Stock Forecast & Price Target

$25.51

-0.07 (-0.27%)

(As of 09/18/2024 ET)

Beam Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 13 Analyst Ratings

Based on 13 Wall Street analysts who have issued ratings for Beam Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 7 have given a hold rating, and 6 have given a buy rating for BEAM.

Consensus Price Target

$44.18
73.19% Upside

High Forecast	$80.00
Average Forecast	$44.18
Low Forecast	$20.00

According to the 13 analysts' twelve-month price targets for Beam Therapeutics, the average price target is $44.18. The highest price target for BEAM is $80.00, while the lowest price target for BEAM is $20.00. The average price target represents a forecasted upside of 73.19% from the current price of $25.51.

Type	Current Forecast 9/19/23 to 9/18/24	1 Month Ago 8/20/23 to 8/19/24	3 Months Ago 6/21/23 to 6/20/24	1 Year Ago 9/19/22 to 9/19/23
Consensus Rating	Hold	Hold	Hold	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	7 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	8 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$44.18	$41.70	$40.18	$63.82
Forecasted Upside	73.19% Upside	59.54% Upside	46.99% Upside	93.43% Upside

War on Elon Escalates… (Ad)

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

BEAM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BEAM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Beam Therapeutics Stock vs. The Competition

Type	Beam Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.46	2.77	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	73.19% Upside	1,010.31% Upside	7.94% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/11/2024	Stifel Nicolaus 4 of 5 stars		Boost Target	Buy ➝ Buy	$66.00 ➝ $69.00	+191.75%
8/22/2024	HC Wainwright 2 of 5 stars	P. Trucchio Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00	+213.85%
8/7/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$45.00 ➝ $48.00	+94.88%
8/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$33.00 ➝ $31.00	+26.69%
8/7/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Sector Perform ➝ Sector Perform	$27.00 ➝ $27.00	+8.39%
8/6/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$57.00	+123.35%
War on Elon Escalates… (Ad) A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it.
3/27/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$57.00	+68.29%
12/15/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$35.00	+17.49%
12/8/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$75.00 ➝ $30.00	+4.35%
10/31/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
10/20/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Foroohar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
10/20/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Bienkowski Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
10/20/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$75.00 ➝ $20.00	+8.93%
8/9/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$46.00 ➝ $47.00	+80.01%
8/9/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$60.00 ➝ $56.00	+113.33%
3/21/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$37.00	+14.80%
3/1/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$125.00 ➝ $105.00	+160.93%
11/15/2022	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$102.00	+107.40%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:48 PM ET.

BEAM Forecast - Frequently Asked Questions

What is Beam Therapeutics' forecast for 2024?: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Beam Therapeutics is $44.18, with a high forecast of $80.00 and a low forecast of $20.00.
Should I buy or sell Beam Therapeutics stock right now?: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last twelve months. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BEAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEAM, but not buy additional shares or sell existing shares.
Does Beam Therapeutics's stock price have much upside?: According to analysts, Beam Therapeutics's stock has a predicted upside of 71.57% based on their 12-month stock forecasts.
What analysts cover Beam Therapeutics?: Beam Therapeutics has been rated by research analysts at Barclays, HC Wainwright, JPMorgan Chase & Co., Royal Bank of Canada, Stifel Nicolaus, and Wedbush in the past 90 days.
Do Wall Street analysts like Beam Therapeutics more than its competitors?: Analysts like Beam Therapeutics less than other "medical" companies. The consensus rating for Beam Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BEAM compares to other companies.